Sunesis pharmaceuticals inc. (SNSS)
CashFlow / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12Dec'11Sep'11Jun'11Mar'11
Cash flows from operating activities
Net loss

-5,775

-5,287

-5,942

-6,241

-5,860

-5,997

-6,505

-6,840

-7,273

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net loss

-

-

-

-

-

-

-

-

-

-

-

-8,842

-9,834

-8,537

-8,954

-10,446

-10,086

-11,578

-7,021

-8,949

-9,128

-1,323

-15,325

-11,781

-14,573

-7,177

-7,607

-8,190

-11,624

-4,052

-17,396

-8,579

-13,924

-8,740

-5,014

-8,227

1,840

Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense

319

473

465

394

417

452

637

652

896

609

501

1,036

887

1,042

1,090

1,206

1,453

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

529

89

255

Accretion of investment discounts and depreciation

-37

-

-

-

2

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Stock-based compensation expense

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,964

-

1,635

1,464

1,306

988

1,033

1,113

751

705

874

577

568

-

-

-

-

Depreciation and amortization

-

-

-

-

-

-

2

2

2

2

3

2

2

3

2

3

3

3

2

11

11

11

7

6

5

4

4

5

7

7

8

8

8

9

9

15

23

Amortization of debt discount and debt issuance costs

4

4

5

65

42

48

48

48

48

52

61

78

78

79

79

79

122

29

31

31

44

67

83

101

116

133

148

164

176

179

83

72

66

-

-

0

0

Write-off debt discount upon note repayment

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

27

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Decrease in fair value of warrant liability

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-1,765

-1,867

89

-10,130

1,634

-333

4,937

-

-

-

-

-

-

-

-

-

-

-

-

(Decrease) increase in fair value of warrant liability

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

722

1,146

-2,852

4,767

-8,150

753

-4,879

177

2,460

-374

3,615

Foreign exchange gain on marketable securities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-32

183

23

-32

116

117

-189

38

-

-419

96

144

Changes in operating assets and liabilities:
Other non-cash items

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

46

Accounts receivable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

4,000

Prepaids and other assets

91

-427

74

556

91

91

-170

4

-988

-29

382

1,497

71

-197

9

130

143

-238

-368

-313

259

-51

151

11

-68

190

20

-186

-513

-8

53

-249

302

-141

330

-155

309

Accounts payable

71

21

78

-169

-532

116

-276

515

-659

156

-736

-370

776

-655

-233

178

128

663

-492

161

-1,056

2,405

259

-498

58

-506

-650

582

1,449

-1,109

794

-476

211

331

-2

-287

200

Accrued clinical expense

79

-23

19

105

-80

-144

92

-18

-197

2

-44

-542

-83

-201

-371

-179

231

45

-340

24

-887

-509

-317

301

-1,113

-88

901

-403

-1,109

786

681

1,418

194

-392

361

802

25

Accrued compensation

-239

-192

308

192

-266

-243

231

93

-578

-141

409

117

-945

513

374

184

-677

115

246

216

-1,258

292

707

417

-848

417

303

321

-787

388

297

200

-694

255

261

265

-520

Other accrued liabilities

-75

905

-291

-686

255

-650

149

-344

223

558

27

-791

143

29

-215

287

-1,163

110

-1,370

1,342

-268

-838

-218

2,131

599

-245

94

-170

245

710

-1,188

1,266

-266

667

-428

701

-424

Deferred revenue

-

-

-

-

-

-

-

-

-

-

-

0

-610

-611

-610

-610

-610

-611

-610

-856

-853

-855

-854

-1,990

-1,988

-1,989

-1,989

-1,989

-1,989

-

-

-

-

-

-

-

-

Net cash used in operating activities

-5,744

-3,748

-5,430

-6,894

-6,113

-6,506

-5,452

-5,896

-6,550

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-9,484

-

13,746

-5,829

-9,298

-7,270

-6,688

-2,163

-6,715

Cash flows from investing activities
Net cash used in operating activities

-

-

-

-

-

-

-

-

-

-

-

-

-9,657

-7,972

-8,847

-9,428

-10,715

-9,276

-9,648

-8,206

-11,601

-9,015

-12,540

-10,193

-11,433

-

-

-

-

-

-

-

-

-

-

-

-

Purchases of property and equipment

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

25

0

23

-

-

-

-

-

-

-

-

0

-1

4

12

Purchases of marketable securities

748

-

-

-

-

-

-

-

-

-

-

-

-

13,144

-35,036

13,908

43,514

11,331

5,425

10,985

7,942

4,516

5,013

20,631

12,303

4,292

3,357

10,689

8,556

32,318

25,965

634

8,691

17,838

6,076

11,639

16,529

Proceeds from maturities of marketable securities

13,705

-

-

-

-

0

3,398

640

742

-273

6,513

12,704

10,830

-2,488

-30,285

6,391

46,913

5,480

10,980

12,740

7,730

7,635

12,881

9,140

16,180

3,842

22,760

16,200

16,308

11,117

8,686

12,495

13,928

12,837

17,048

9,500

16,856

Net cash provided by investing activities

-

-

-

-

-

-

-

-

-

-

-

-

10,830

-16,122

5,241

-7,517

3,399

-5,851

5,555

1,755

-212

3,119

7,843

-11,491

3,854

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by investing activities

12,957

-

-

-

-

0

3,398

640

742

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

7,752

-

-17,279

11,861

5,237

-5,002

11,008

-2,143

315

Cash flows from financing activities
Proceeds from notes payable, net of issuance cost

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

2,500

12,500

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Principal payments on notes payable

-

0

0

6,094

1,406

-

-

-

-

-

-

-

-

0

7,153

0

830

0

0

0

1,642

2,419

2,364

2,312

2,261

2,211

2,162

2,115

694

-

-

-

-

-

-

-

-

Payoff of notes payable and final payment

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

7,153

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Payment of financing fees and debt issuance costs

-

-

-

-

-

-

-

-

-

-

-

-

-

0

37

0

229

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from issuance of convertible preferred stock offering, net

-

0

4,654

-65

7,944

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from issuance of common stock, net

-

-46

21,406

-28

10,690

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from issuance of common stock and warrants

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

12

-10

40,022

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from issuance of common stock through controlled equity offering facilities, net

-

-

-

-

-

0

5,189

819

32

-

-

-

-

-

-

-

-

0

450

7,664

10,011

9,566

0

0

4,726

-

-

-

-

-

-

-

-

0

0

1,962

2,091

Proceeds from exercise of stock options and stock purchase rights

-

-

-

-

-

40

-1

100

164

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from exercise of warrants, stock options and stock purchase rights

-

-

-

-

-

-

-

-

-

-

-

-2,108

2,241

-

-

-

-

44

142

305

42

128

1,095

413

325

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by financing activities

-

-

-

-

-

-

-

-

-

-

-

-

2,241

26,325

-16

2,534

4,288

25,212

592

7,969

8,411

7,275

-1,257

-1,909

42,812

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from exercise of warrants and stock options

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

41

-

-

-

-

-

-

-

-

Proceeds from exercise of warrants, stock options and stock purchase rights

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

331

157

32

64

0

4

0

Net cash provided by financing activities

-

-19

26,060

-234

17,228

40

5,188

919

196

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-653

-

33,415

429

32

9,689

0

1,966

2,091

Net increase in cash, cash equivalents and restricted cash

7,213

-6,972

9,936

-9,514

11,115

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Conversion of preferred stock to common stock

-

0

0

18,534

3,228

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Right-of-use assets obtained in exchange for new operating lease liabilities

-

-

-

-

1,362

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net increase (decrease) in cash and cash equivalents

-

-

-

-

-

-

-

-

-5,612

19,030

-3,725

202

3,414

2,231

-3,622

-14,411

-3,028

10,085

-3,501

1,518

-3,402

1,379

-5,954

-23,593

35,233

-6,611

15,127

-5,950

-2,385

-26,685

29,882

6,461

-4,029

-2,583

4,320

-2,340

-4,309

Fair value of warrants issued in connection with notes payable

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-1

0

537

-

0

0

100

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Legal expenses accrued as cost of equity financing

-

-

-28

93

-98

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-